Q2 2025 Earnings Call February 4, 2025 8:00 AM ETCompany ParticipantsBen Krasinski - Senior Director, IRMichael J.

Alnylam Pharmaceuticals (NASDAQ:ALNY), with a market capitalization of $35.4 billion, has emerged as a leading player in the RNA interference (RNAi) therapeutics space, with a particular focus on ...

Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for ...

Medical Devices conference, held in Munich, Germany on 28-29 January, was filled with sessions that dug into the minutiae of ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...